Protein targets of inflammatory serine proteases and cardiovascular disease

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Sharony, Ram ^a   Yu, Pey Jen ^b   Park, Joy ^b   Galloway, Aubrey C ^b   Mignatti, Paolo ^b   Pintucci, Giuseppe ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; C REACTIVE PROTEIN; CATHEPSIN G; CHYMASE; COLLAGEN; ELASTASE; ELASTIN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 8; KALLIKREIN; LEUKOCYTE ELASTASE; OSTEOPONTIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; RANTES; SERINE PROTEINASE; THROMBIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CORONARY RISK; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; HEART INFARCTION; HUMAN; INFLAMMATION; MAST CELL; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; VALVULAR HEART DISEASE; VASCULAR ENDOTHELIUM;

EID: 77956488518     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-45     Document Type: Review

References (188)

1. Macrophages and atherosclerotic plaque stability. P Libby YJ Geng M Aikawa U Schoenbeck F Mach SK Clinton GK Sukhova RT Lee, Curr Opin Lipidol 1996 7 330 335 10.1097/00041433-199610000-00012 8937525
2. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. T Suganami J Nishida Y Ogawa, Arterioscler Thromb Vasc Biol 2005 25 2062 2068 10.1161/01.ATV.0000183883.72263.13 16123319
3. Role of polymorphonuclear leukocytes in collar-induced intimal thickening in the rabbit carotid artery. DJ Van Put N Van Osselaer GR De Meyer LJ Andries MM Kockx LS De Clerck H Bult, Arterioscler Thromb Vasc Biol 1998 18 915 921 9633931
4. Modulation of the inflammatory response in cardiovascular disease. DN Granger T Vowinkel T Petnehazy, Hypertension 2004 43 924 931 10.1161/01.HYP.0000123070.31763.55 15007038
5. Mechanisms of contraction induced by human leukocytes in normal and atherosclerotic arteries. A Mugge DD Heistad RC Padgett BJ Waack P Densen JA Lopez, Circ Res 1991 69 871 880 1873879
6. The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. S Marcondes E Antunes, Curr Med Chem Cardiovasc Hematol Agents 2005 3 33 44 10.2174/1568016052773351 15638742
7. Mast cell proteases: multifaceted regulators of inflammatory disease. G Pejler E Ronnberg I Waern S Wernersson, Blood 2010 115 4981 4990 10.1182/blood-2010-01-257287 20233968
8. Thrombin-induced alterations in endothelial permeability. AB Malik SK Lo R Bizios, Ann N Y Acad Sci 1986 485 293 309 10.1111/j.1749-6632.1986.tb34591.x 3032047
9. Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and-2. R Sharony G Pintucci PC Saunders EA Grossi FG Baumann AC Galloway P Mignatti, Am J Physiol Heart Circ Physiol 2006 290 1651 1659 10.1152/ajpheart.00530.2005 16284240
10. A genomic view of the complexity of mammalian proteolytic systems. XS Puente LM Sanchez A Gutierrez-Fernandez G Velasco C Lopez-Otin, Biochem Soc Trans 2005 33 331 334 10.1042/BST0330331 15787599
11. A genomic analysis of rat proteases and protease inhibitors. XS Puente C Lopez-Otin, Genome Res 2004 14 609 622 10.1101/gr.1946304 15060002
12. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. R Ramachandran MD Hollenberg, Br J Pharmacol 2008 153 Suppl 1 263 282 10.1038/sj.bjp.0707507 18059329
13. Tissue destruction by neutrophils. SJ Weiss, N Engl J Med 1989 320 365 376 10.1056/NEJM198902093200606 2536474
14. Protease-activated receptors in cardiovascular diseases. AJ Leger L Covic A Kuliopulos, Circulation 2006 114 1070 1077 10.1161/CIRCULATIONAHA.105.574830 16952995
15. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. MD Hollenberg SJ Compton, Pharmacol Rev 2002 54 203 217 10.1124/pr.54.2.203 12037136
16. Science review: role of coagulation protease cascades in sepsis. M Riewald W Ruf, Crit Care 2003 7 123 129 10.1186/cc1825 12720558
17. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. K Borensztajn MP Peppelenbosch CA Spek, Trends Mol Med 2008 14 429 440 10.1016/j.molmed.2008.08.001 18774340
18. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. SL Jacques M LeMasurier PJ Sheridan SK Seeley A Kuliopulos, J Biol Chem 2000 275 40671 40678 10.1074/jbc.M004544200 11005807
19. Domains specifying thrombin-receptor interaction. TK Vu VI Wheaton DT Hung I Charo SR Coughlin, Nature 1991 353 674 677 10.1038/353674a0 1717851
20. Mammalian G proteins and their cell type specific functions. N Wettschureck S Offermanns, Physiol Rev 2005 85 1159 1204 10.1152/physrev.00003. 2005 16183910
21. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. M Steinhoff J Buddenkotte V Shpacovitch A Rattenholl C Moormann N Vergnolle TA Luger MD Hollenberg, Endocr Rev 2005 26 1 43 10.1210/er.2003-0025 15689571
22. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. RM Scarborough MA Naughton W Teng DT Hung J Rose TK Vu VI Wheaton CW Turck SR Coughlin, J Biol Chem 1992 267 13146 13149 1320011
23. Thrombin and phenotypic modulation of the endothelium. T Minami A Sugiyama SQ Wu R Abid T Kodama WC Aird, Arterioscler Thromb Vasc Biol 2004 24 41 53 10.1161/01.ATV.0000099880.09014.7D 14551154
24. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. RE Gerszten J Chen M Ishii K Ishii L Wang T Nanevicz CW Turck TK Vu SR Coughlin, Nature 1994 368 648 651 10.1038/368648a0 8145852
25. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. L Covic AL Gresser J Talavera S Swift A Kuliopulos, Proc Natl Acad Sci USA 2002 99 643 648 10.1073/pnas. 022460899 11805322
26. Defective platelet activation in G alpha(q)-deficient mice. S Offermanns CF Toombs YH Hu MI Simon, Nature 1997 389 183 186 10.1038/38284 9296496
27. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. C Trumel B Payrastre M Plantavid B Hechler C Viala P Presek EA Martinson JP Cazenave H Chap C Gachet, Blood 1999 94 4156 4165 10590060
28. Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. JG Garcia C Patterson C Bahler J Aschner CM Hart D English, J Cell Physiol 1993 156 541 549 10.1002/jcp.1041560313 8360259
29. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. JG Garcia HW Davis CE Patterson, J Cell Physiol 1995 163 510 522 10.1002/jcp.1041630311 7775594
30. Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells. V Vouret-Craviari C Bourcier E Boulter E van Obberghen-Schilling, J Cell Sci 2002 115 2475 2484 12045218
31. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. C Feistritzer M Riewald, Blood 2005 105 3178 3184 10.1182/blood-2004-10-3985 15626732
32. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. LO Mosnier AJ Gale S Yegneswaran JH Griffin, Blood 2004 104 1740 1744 10.1182/blood-2004-01-0110 15178575
33. Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy. A Donati M Romanelli L Botticelli A Valentini V Gabbanelli S Nataloni T Principi P Pelaia R Bezemer C Ince, Crit Care 2009 13 Suppl 5 12 10.1186/cc8010 19951384
34. Caveolae are required for protease-selective signaling by protease-activated receptor-1. A Russo UJ Soh MM Paing P Arora J Trejo, Proc Natl Acad Sci USA 2009 106 6393 6397 10.1073/pnas.0810687106 19332793
35. Thrombin receptor expression in normal and atherosclerotic human arteries. NA Nelken SJ Soifer J O'Keefe TK Vu IF Charo SR Coughlin, J Clin Invest 1992 90 1614 1621 10.1172/JCI116031 1328304
36. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. CA McNamara IJ Sarembock LW Gimple JW Fenton SR Coughlin GK Owens, J Clin Invest 1993 91 94 98 10.1172/JCI116206 8380817
37. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. M Takada H Tanaka T Yamada O Ito M Kogushi M Yanagimachi T Kawamura T Musha F Yoshida M Ito, et al. Circ Res 1998 82 980 987 9598595
38. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. JS Ahn S Choi SH Jang HJ Chang JH Kim KB Nahm SW Oh EY Choi, Clin Chim Acta 2003 332 51 59 10.1016/S0009-8981(03)00113-X 12763280
39. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. DD Ku JK Zaleski, J Cardiovasc Pharmacol 1993 22 609 616 10.1097/00005344-199310000-00015 7505364
40. Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. DD Ku J Dai, J Cardiovasc Pharmacol 1997 30 649 657 10.1097/00005344-199711000-00016 9388048
41. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. A Boire L Covic A Agarwal S Jacques S Sherifi A Kuliopulos, Cell 2005 120 303 313 10.1016/j.cell.2004.12.018 15707890
42. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. JF Keuren SJ Wielders H Ulrichts T Hackeng JW Heemskerk H Deckmyn EM Bevers T Lindhout, Arterioscler Thromb Vasc Biol 2005 25 1499 1505 10.1161/01.ATV.0000167526.31611. f6 15845904
43. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. AJ Leger SL Jacques J Badar NC Kaneider CK Derian P Andrade-Gordon L Covic A Kuliopulos, Circulation 2006 113 1244 1254 10.1161/CIRCULATIONAHA.105.587758 16505172
44. Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems. KK Hansen K Oikonomopoulou Y Li MD Hollenberg, Naunyn Schmiedebergs Arch Pharmacol 2008 377 377 392 10.1007/s00210-007-0194-2 17952408
45. Role of protease-activated receptors in the vascular system. K Hirano H Kanaide, J Atheroscler Thromb 2003 10 211 225 14566084
46. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. D Carden F Xiao C Moak BH Willis S Robinson-Jackson S Alexander, Am J Physiol 1998 275 385 392 9683424
47. Neutrophil-mediated epithelial injury during transmigration: role of elastase. HH Ginzberg V Cherapanov Q Dong A Cantin CA McCulloch PT Shannon GP Downey, Am J Physiol Gastrointest Liver Physiol 2001 281 705 717 11518683
48. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. M Bedard CD McClure NL Schiller C Francoeur A Cantin M Denis, Am J Respir Cell Mol Biol 1993 9 455 462 7691110
49. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. H Nakamura K Yoshimura NG McElvaney RG Crystal, J Clin Invest 1992 89 1478 1484 10.1172/JCI115738 1569186
50. IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. A Ariel EJ Yavin R Hershkoviz A Avron S Franitza I Hardan L Cahalon M Fridkin O Lider, J Immunol 1998 161 2465 2472 9725245
51. Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. HM Morrison JA Kramps D Burnett RA Stockley, Clin Sci (Lond) 1987 72 373 381 2434283
52. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. G Ortiz-Munoz X Houard JL Martin-Ventura BY Ishida S Loyau P Rossignol JA Moreno JP Kane RJ Chalkley AL Burlingame, et al. FASEB J 2009 23 3129 3139 10.1096/fj.08-127928 19417089
53. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. D Ardissino PA Merlini R Ariens R Coppola E Bramucci PM Mannucci, Lancet 1997 349 769 771 10.1016/S0140-6736(96)11189-2 9074577
54. Tissue factor in the pathogenesis of atherosclerosis. MB Taubman JT Fallon AD Schecter P Giesen M Mendlowitz BS Fyfe JD Marmur Y Nemerson, Thromb Haemost 1997 78 200 204 9198153
55. Effect of smoking on plasma neutrophil elastase levels. RT Abboud T Fera S Johal A Richter N Gibson, J Lab Clin Med 1986 108 294 300 3639117
56. Neutrophil activation detected by increased neutrophil elastase activity in type 1 (insulin-dependent) diabetes mellitus. A Collier M Jackson D Bell AW Patrick DM Matthews RJ Young BF Clarke J Dawes, Diabetes Res 1989 10 135 138 2805587
57. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. CM Dollery CA Owen GK Sukhova A Krettek SD Shapiro P Libby, Circulation 2003 107 2829 2836 10.1161/01.CIR.0000072792.65250.4A 12771009
58. The cell biology of leukocyte-mediated proteolysis. CA Owen EJ Campbell, J Leukoc Biol 1999 65 137 150 10088596
59. The elastolytic activity of cathepsin G: an ex vivo study with dermal elastin. C Boudier G Godeau W Hornebeck L Robert JG Bieth, Am J Respir Cell Mol Biol 1991 4 497 503 1711351
60. Comparison of the proteoglycanolytic activities of human leukocyte elastase and human cathepsin G in vitro and in vivo. J McDonnell JM Lobner WB Knight MW Lark B Green M Poe VL Moore, Connect Tissue Res 1993 30 1 9 10.3109/03008209309032926 8149741
61. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. P Shamamian JD Schwartz BJ Pocock S Monea D Whiting SG Marcus P Mignatti, J Cell Physiol 2001 189 197 206 10.1002/jcp.10014 11598905
62. Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. N Shimoda N Fukazawa K Nonomura RL Fairchild, Am J Pathol 2007 170 930 940 10.2353/ajpath.2007.060486 17322378
63. Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. A Sabri SG Alcott H Elouardighi E Pak C Derian P Andrade-Gordon K Kinnally SF Steinberg, J Biol Chem 2003 278 23944 23954 10.1074/jbc.M302718200 12707281
64. Novel mode for neutrophil protease cathepsin G-mediated signaling: membrane shedding of epidermal growth factor is required for cardiomyocyte anoikis. K Rafiq M Hanscom K Valerie SF Steinberg A Sabri, Circ Res 2008 102 32 41 10.1161/CIRCRESAHA.107.150573 17975113
65. CC chemokine receptor-1 activates intimal smooth muscle-like cells in graft arterial disease. K Shimizu M Minami R Shubiki M Lopez-Ilasaca L MacFarlane Y Asami Y Li RN Mitchell P Libby, Circulation 2009 120 1800 1813 10.1161/CIRCULATIONAHA.109.859595 19841301
66. Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. K Vogiatzi V Voudris S Apostolakis GE Kochiadakis S Thomopoulou A Zaravinos DA Spandidos, Thromb Res 2009 124 84 89 10.1016/j.thromres.2008.12.043 19201454
67. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. JK Lim W Lu O Hartley AL DeVico, J Leukoc Biol 2006 80 1395 1404 10.1189/jlb.0406290 16963625
68. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. JK Lim JM Burns W Lu AL DeVico, J Leukoc Biol 2005 78 442 452 10.1189/jlb.0305161 15923218
69. Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. T Omura M Yoshiyama S Kim R Matsumoto Y Nakamura Y Izumi H Ichijo T Sudo K Akioka H Iwao, et al. Arterioscler Thromb Vasc Biol 2004 24 270 275 10.1161/01.ATV.0000112930.40564.89 14684425
70. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. S Helske S Syvaranta M Kupari J Lappalainen M Laine J Lommi H Turto M Mayranpaa K Werkkala PT Kovanen KA Lindstedt, Eur Heart J 2006 27 1495 1504 10.1093/eurheartj/ehi706 16401677
71. Cathepsin G is associated with atheroma formation in human carotid artery. L Legedz J Randon C Sessa JP Baguet P Feugier C Cerutti J McGregor G Bricca, J Hypertens 2004 22 157 166 10.1097/00004872-200401000-00025 15106807
72. Inflammation in the course of early myocardial ischemia. ML Entman L Michael RD Rossen WJ Dreyer DC Anderson AA Taylor CW Smith, FASEB J 1991 5 2529 2537 1868978
73. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. JL Romson BG Hook SL Kunkel GD Abrams MA Schork BR Lucchesi, Circulation 1983 67 1016 1023 6831665
74. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection. SD Bergese EH Huang RP Pelletier MB Widmer RM Ferguson CG Orosz, Am J Pathol 1995 147 166 175 7541609
75. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. M Takada KC Nadeau GD Shaw KA Marquette NL Tilney, J Clin Invest 1997 99 2682 2690 10.1172/JCI119457 9169498
76. Postischemic renal injury is mediated by neutrophils and leukotrienes. JM Klausner IS Paterson G Goldman L Kobzik C Rodzen R Lawrence CR Valeri D Shepro HB Hechtman, Am J Physiol 1989 256 794 802 2541628
77. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. M Miura X Fu QW Zhang DG Remick RL Fairchild, Am J Pathol 2001 159 2137 2145 11733364
78. In vitro processing of human tumor necrosis factor-alpha. S Robache-Gallea V Morand JM Bruneau B Schoot E Tagat E Realo S Chouaib S Roman-Roman, J Biol Chem 1995 270 23688 23692 10.1074/jbc.270.40.23688 7559538
79. Pro-tumour necrosis factor cleavage enzyme in macrophage membrane/particulate. KU Kim OJ Kwon DM Jue, Immunology 1993 80 134 139 8244455
80. Suppression of human leukocyte tumor necrosis factor secretion by the serine protease inhibitor p-toluenesulfonyl-L-arginine methyl ester (TAME). P Scuderi, J Immunol 1989 143 168 173 2499627
81. Effects of elastase and cathepsin G on the levels of membrane and soluble TNFalpha. R Mezyk-Kopec M Bzowska B Mickowska P Mak J Potempa J Bereta, Biol Chem 2005 386 801 811 10.1515/BC.2005.094 16201876
82. Inactivation of recombinant human tumor necrosis factor-alpha by proteolytic enzymes released from stimulated human neutrophils. KP van Kessel JA van Strijp J Verhoef, J Immunol 1991 147 3862 3868 1940372
83. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. LA Joosten FA van De Loo E Lubberts MM Helsen MG Netea JW van Der Meer CA Dinarello WB van Den Berg, J Immunol 2000 165 6553 6558 11086098
84. Defective NK cell activity and Th1 response in IL-18-deficient mice. K Takeda H Tsutsui T Yoshimoto O Adachi N Yoshida T Kishimoto H Okamura K Nakanishi S Akira, Immunity 1998 8 383 390 10.1016/S1074-7613(00)80543-9 9529155
85. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. H Tsutsui N Kayagaki K Kuida H Nakano N Hayashi K Takeda K Matsui S Kashiwamura T Hada S Akira, et al. Immunity 1999 11 359 367 10.1016/S1074-7613(00)80111-9 10514014
86. Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation. U Bank D Reinhold C Schneemilch D Kunz HJ Synowitz S Ansorge, J Interferon Cytokine Res 1999 19 1277 1287 10.1089/107999099312957 10574621
87. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. F Porteu M Brockhaus D Wallach H Engelmann CF Nathan, J Biol Chem 1991 266 18846 18853 1655765
88. Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear leukocytes? G Pintucci L Iacoviello MP Castelli C Amore V Evangelista C Cerletti MB Donati, J Lab Clin Med 1993 122 69 79 8320493
89. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. JJ Yang R Kettritz RJ Falk JC Jennette ML Gaido, Am J Pathol 1996 149 1617 1626 8909251
90. Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways. GA Preston CS Zarella WF Pendergraft EH Rudolph JJ Yang SB Sekura JC Jennette RJ Falk, J Am Soc Nephrol 2002 13 2840 2849 10.1097/01.ASN.0000034911.03334.C3 12444202
91. The inhibition of neutrophil elastase ameliorates mouse liver damage due to ischemia and reperfusion. Y Uchida MC Freitas D Zhao RW Busuttil JW Kupiec-Weglinski, Liver Transpl 2009 15 939 947 10.1002/lt.21770 19642132
92. C-reactive protein products generated by neutrophil elastase promote neutrophil apoptosis. Y Kakuta K Aoshiba A Nagai, Arch Med Res 2006 37 456 460 10.1016/j.arcmed.2005.10.010 16624642
93. Leukocyte elastase induces epithelial apoptosis: role of mitochondial permeability changes and Akt. HH Ginzberg PT Shannon T Suzuki O Hong E Vachon T Moraes MT Abreu V Cherepanov X Wang CW Chow GP Downey, Am J Physiol Gastrointest Liver Physiol 2004 287 286 298 10.1152/ajpgi.00350.2003 15194561
94. Cell signaling by receptor tyrosine kinases. J Schlessinger, Cell 2000 103 211 225 10.1016/S0092-8674(00)00114-8 11057895
95. Genetic therapies for cardiovascular diseases. LG Melo AS Pachori M Gnecchi VJ Dzau, Trends Mol Med 2005 11 240 250 10.1016/j.molmed.2005.03.008 15882612
96. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. AK Mitra DM Gangahar DK Agrawal, Immunol Cell Biol 2006 84 115 124 10.1111/j.1440-1711.2005.01407.x 16519729
97. Molecular mechanisms in intimal hyperplasia. AC Newby AB Zaltsman, J Pathol 2000 190 300 309 10.1002/(SICI)1096-9896(200002)190:3<300:AID- PATH596>3.0.CO;2-I 10685064
98. Role of thrombin in angiogenesis and tumor progression. NE Tsopanoglou ME Maragoudakis, Semin Thromb Hemost 2004 30 63 69 10.1055/s-2004-822971 15034798
99. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. A Kalmes BR Vesti G Daum JA Abraham AW Clowes, Circ Res 2000 87 92 98 10903991
100. Requirement of an intermediate gene expression for biphasic ERK1/2 activation in thrombin-stimulated vascular smooth muscle cells. AP Sastre S Grossmann HP Reusch M Schaefer, J Biol Chem 2008 283 25871 25878 10.1074/jbc.M800949200 18650426
101. Biology of platelet-derived growth factor and its involvement in disease. RH Alvarez HM Kantarjian JE Cortes, Mayo Clin Proc 2006 81 1241 1257 10.4065/81.9.1241 16970222
102. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. E Millette BH Rauch O Defawe RD Kenagy G Daum AW Clowes, Circ Res 2005 96 172 179 10.1161/01.RES.0000154595.87608.db 15625285
103. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. M Benezra I Vlodavsky R Ishai-Michaeli G Neufeld R Bar-Shavit, Blood 1993 81 3324 3331 8507869
104. The endogenous immune response modulates the course of IgA-immune complex mediated nephropathy. TK Chao A Rifai SM Ka SM Yang HA Shui YF Lin HK Sytwu WH Lee JT Kung A Chen, Kidney Int 2006 70 283 297 10.1038/sj.ki.5001533 16738538
105. Autocrine production of basic fibroblast growth factor translated from novel synthesized mRNA mediates thrombin-induced mitogenesis in smooth muscle cells. A Cucina V Borrelli M Lucarelli AV Sterpetti A Cavallaro R Strom L Santoro-D'Angelo S Scarpa, Cell Biochem Funct 2002 20 39 46 10.1002/cbf.938 11835269
106. Thrombin-and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. BH Rauch E Millette RD Kenagy G Daum AW Clowes, Circ Res 2004 94 340 345 10.1161/01.RES.0000111805.09592.D8 14670838
107. Cholesterol enhances thrombin-induced release of fibroblast growth factor-2 in human vascular smooth muscle cells. BH Rauch GA Scholz D Baumgartel-Allekotte P Censarek JW Fischer AA Weber K Schror, Arterioscler Thromb Vasc Biol 2007 27 20 25 10.1161/01.ATV.0000258793.51013.34 17255536
108. The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells. GA Stouffer MS Runge, Semin Thromb Hemost 1998 24 145 150 10.1055/s-2007-995833 9579635
109. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. RH Weiss M Maduri, J Biol Chem 1993 268 5724 5727 8449935
110. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. G Pintucci D Moscatelli F Saponara PR Biernacki FG Baumann C Bizekis AC Galloway C Basilico P Mignatti, FASEB J 2002 16 598 600 11919166
111. Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases. G Pintucci BM Steinberg G Seghezzi J Yun A Apazidis FG Baumann EA Grossi SB Colvin P Mignatti AC Galloway, Surgery 1999 126 422 427 10455916
112. Evolution of the Fgf and Fgfr gene families. N Itoh DM Ornitz, Trends Genet 2004 20 563 569 10.1016/j.tig.2004.08.007 15475116
113. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. RZ Florkiewicz A Sommer, Proc Natl Acad Sci USA 1989 86 3978 3981 10.1073/pnas.86.11.3978 2726761
114. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. S Vagner MC Gensac A Maret F Bayard F Amalric H Prats AC Prats, Mol Cell Biol 1995 15 35 44 7799942
115. Functional diversity of FGF-2 isoforms by intracellular sorting. V Sorensen T Nilsen A Wiedlocha, Bioessays 2006 28 504 514 10.1002/bies.20405 16615083
116. Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. PJ Yu G Ferrari AC Galloway P Mignatti G Pintucci, J Cell Biochem 2007 100 1100 1108 10.1002/jcb.21116 17131363
117. Molecular pathology of the fibroblast growth factor family. P Krejci J Prochazkova V Bryja A Kozubik WR Wilcox, Hum Mutat 2009 30 1245 1255 10.1002/humu.21067 19621416
118. What is all that thrombin for? KG Mann K Brummel S Butenas, J Thromb Haemost 2003 1 1504 1514 10.1046/j.1538-7836.2003.00298.x 12871286
119. Tissue factor, thrombin, and cancer. FR Rickles S Patierno PM Fernandez, Chest 2003 124 58S 68S 10.1378/chest.124.3-suppl.58S 12970125
120. Thrombin receptor overexpression in malignant and physiological invasion processes. S Even-Ram B Uziely P Cohen S Grisaru-Granovsky M Maoz Y Ginzburg R Reich I Vlodavsky R Bar-Shavit, Nat Med 1998 4 909 914 10.1038/nm0898-909 9701242
121. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. NE Tsopanoglou ME Maragoudakis, J Biol Chem 1999 274 23969 23976 10.1074/jbc.274.34.23969 10446165
122. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. TO Daniel VC Gibbs DF Milfay MR Garovoy LT Williams, J Biol Chem 1986 261 9579 9582 2426251
123. Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. E Papadimitriou VG Manolopoulos GT Hayman ME Maragoudakis BR Unsworth JW Fenton PI Lelkes, Am J Physiol 1997 272 1112 1122 9142835
124. Protease-activated receptors in hemostasis, thrombosis and vascular biology. SR Coughlin, J Thromb Haemost 2005 3 1800 1814 10.1111/j.1538-7836. 2005.01377.x 16102047
125. Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. H Cao N Dronadula GN Rao, Am J Physiol Cell Physiol 2006 290 172 182 10.1152/ajpcell.00284.2005 16148030
126. Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity. PJ Yu G Ferrari L Pirelli AC Galloway P Mignatti G Pintucci, Oncogene 2008 27 2594 2601 10.1038/sj.onc.1210899 17968311
127. The emerging roles of human tissue kallikreins in cancer. CA Borgono EP Diamandis, Nat Rev Cancer 2004 4 876 890 10.1038/nrc1474 15516960
128. Human tissue kallikreins: physiologic roles and applications in cancer. CA Borgono IP Michael EP Diamandis, Mol Cancer Res 2004 2 257 280 15192120
129. Functional roles of human kallikrein-related peptidases. G Sotiropoulou G Pampalakis EP Diamandis, J Biol Chem 2009 284 32989 32994 10.1074/jbc.R109. 027946 19819870
130. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. CA Borgono L Grass A Soosaipillai GM Yousef CD Petraki DH Howarth S Fracchioli D Katsaros EP Diamandis, Cancer Res 2003 63 9032 9041 14695222 (Pubitemid 38064085)
131. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. H Kim A Scorilas D Katsaros GM Yousef M Massobrio S Fracchioli R Piccinno G Gordini EP Diamandis, Br J Cancer 2001 84 643 650 10.1054/bjoc.2000.1649 11237385 (Pubitemid 32238998)
132. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. SI Blaber B Ciric GP Christophi MJ Bernett M Blaber M Rodriguez IA Scarisbrick, FASEB J 2004 18 920 922 15033932
133. Activity of a newly identified serine protease in CNS demyelination. IA Scarisbrick SI Blaber CF Lucchinetti CP Genain M Blaber M Rodriguez, Brain 2002 125 1283 1296 10.1093/brain/awf142 12023317
134. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. K Oikonomopoulou EP Diamandis MD Hollenberg, Biol Chem 2010 391 299 310 10.1515/BC.2010.038 20180639
135. Proteinase-activated receptors, targets for kallikrein signaling. K Oikonomopoulou KK Hansen M Saifeddine I Tea M Blaber SI Blaber I Scarisbrick P Andrade-Gordon GS Cottrell NW Bunnett, et al. J Biol Chem 2006 281 32095 32112 10.1074/jbc.M513138200 16885167
136. Detection of functional receptors for the proteinase-activated-receptor- 2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. B al-Ani M Saifeddine MD Hollenberg, Can J Physiol Pharmacol 1995 73 1203 1207 8564891
137. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. MD Hollenberg M Saifeddine S Sandhu S Houle N Vergnolle, Br J Pharmacol 2004 143 443 454 10.1038/sj.bjp.0705946 15451771
138. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. N Vergnolle CK Derian MR D'Andrea M Steinhoff P Andrade-Gordon, J Immunol 2002 169 1467 1473 12133973
139. Protease-activated receptors in inflammation, neuronal signaling and pain. N Vergnolle JL Wallace NW Bunnett MD Hollenberg, Trends Pharmacol Sci 2001 22 146 152 10.1016/S0165-6147(00)01634-5 11239578
140. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. FJ Meloni EJ Gustafson AH Schmaier, Blood 1992 79 1233 1244 1536948
141. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. A Ichinose K Fujikawa T Suyama, J Biol Chem 1986 261 3486 3489 3081506
142. Mast cell proteases. G Pejler M Abrink M Ringvall S Wernersson, Adv Immunol 2007 95 167 255 full-text 17869614
143. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. P Berger DW Perng H Thabrew SJ Compton JA Cairns AR McEuen R Marthan JM Tunon De Lara AF Walls, J Appl Physiol 2001 91 1372 1379 11509538
144. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). MS Stack DA Johnson, J Biol Chem 1994 269 9416 9419 8144524
145. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Taipale J Lohi J Saarinen PT Kovanen J Keski-Oja, J Biol Chem 1995 270 4689 4696 10.1074/jbc.270.9.4689 7876240
146. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. LJ Dell'Italia A Husain, Curr Opin Cardiol 2002 17 374 379 10.1097/00001573-200207000-00009 12151872
147. The fibrinogenolytic activity of purified tryptase from human lung mast cells. LB Schwartz TR Bradford BH Littman BU Wintroub, J Immunol 1985 135 2762 2767 3161948
148. Properties of the insulin receptor of isolated fat cell membranes. P Cuatrecasas, J Biol Chem 1971 246 7265 7274 5167021
149. Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. T Kono FW Barham, J Biol Chem 1971 246 6204 6209 4331385
150. Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. SE Shoelson MF White CR Kahn, J Biol Chem 1988 263 4852 4860 2832409
151. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. MA Lafleur MD Hollenberg SJ Atkinson V Knauper G Murphy DR Edwards, Biochem J 2001 357 107 115 10.1042/0264-6021: 3570107 11415441
152. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. PM Ridker CH Hennekens JE Buring N Rifai, N Engl J Med 2000 342 836 843 10.1056/NEJM200003233421202 10733371 (Pubitemid 30165206)
153. Neutrophil lysosomal degradation of human CRP: CRP-derived peptides modulate neutrophil function. EG Shephard R Anderson SM Beer CE Van Rensburg FC de Beer, Clin Exp Immunol 1988 73 139 145 3168329
154. Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. W Zhong Q Zen J Tebo K Schlottmann M Coggeshall RF Mortensen, J Immunol 1998 161 2533 2540 9725253
155. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. SP Ballou G Lozanski, Cytokine 1992 4 361 368 10.1016/1043-4666(92)90079-7 1420997
156. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. V Pasceri JS Cheng JT Willerson ET Yeh, Circulation 2001 103 2531 2534 11382718
157. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. J Cermak NS Key RR Bach J Balla HS Jacob GM Vercellotti, Blood 1993 82 513 520 8329706
158. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. A Nakagomi SB Freedman CL Geczy, Circulation 2000 101 1785 1791 10769278
159. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. S Verma SH Li MV Badiwala RD Weisel PW Fedak RK Li B Dhillon DA Mickle, Circulation 2002 105 1890 1896 10.1161/01.CIR.0000015126.83143.B4 11997273
160. Mechanisms of c-reactive protein up-regulation in arterialized vein grafts. I Gulkarov G Pintucci K Bohmann PC Saunders RF Sullivan G Ferrari P Mignatti AC Galloway, Surgery 2006 139 254 262 10.1016/j.surg.2005.08.002 16455335
161. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. SK Venugopal S Devaraj I Yuhanna P Shaul I Jialal, Circulation 2002 106 1439 1441 10.1161/01.CIR.0000033116. 22237.F9 12234944
162. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. SK Venugopal S Devaraj I Jialal, Circulation 2003 108 1676 1678 10.1161/01.CIR.0000094736.10595.A1 14504187
163. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. S Devaraj DY Xu I Jialal, Circulation 2003 107 398 404 10.1161/01.CIR.0000052617.91920.FD 12551862
164. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. HD Danenberg AJ Szalai RV Swaminathan L Peng Z Chen P Seifert WP Fay DI Simon ER Edelman, Circulation 2003 108 512 515 10.1161/01.CIR.0000085568.13915.1E 12874178
165. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. L Liaw DM Lombardi MM Almeida SM Schwartz D deBlois CM Giachelli, Arterioscler Thromb Vasc Biol 1997 17 188 193 9012655
166. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. M Scatena L Liaw CM Giachelli, Arterioscler Thromb Vasc Biol 2007 27 2302 2309 10.1161/ATVBAHA.107.144824 17717292
167. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. ER O'Brien MR Garvin DK Stewart T Hinohara JB Simpson SM Schwartz CM Giachelli, Arterioscler Thromb 1994 14 1648 1656 7918316
168. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. R Ohmori Y Momiyama H Taniguchi R Takahashi M Kusuhara H Nakamura F Ohsuzu, Atherosclerosis 2003 170 333 337 10.1016/S0021-9150(03) 00298-3 14612215
169. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. R Kato Y Momiyama R Ohmori N Tanaka H Taniguchi K Arakawa M Kusuhara H Nakamura F Ohsuzu, Arterioscler Thromb Vasc Biol 2006 26 1 2 10.1161/01.ATV.0000194157.26665.e6 16373617
170. Association between osteopontin and human abdominal aortic aneurysm. J Golledge J Muller N Shephard P Clancy L Smallwood C Moran AE Dear LJ Palmer PE Norman, Arterioscler Thromb Vasc Biol 2007 27 655 660 10.1161/01.ATV.0000255560. 49503.4e 17170369
171. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. B Christensen L Schack E Klaning ES Sorensen, J Biol Chem 2010 285 7929 7937 10.1074/jbc.M109.075010 20071328
172. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). R Agnihotri HC Crawford H Haro LM Matrisian MC Havrda L Liaw, J Biol Chem 2001 276 28261 28267 10.1074/jbc.M103608200 11375993
173. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. Y Yokosaki N Matsuura T Sasaki I Murakami H Schneider S Higashiyama Y Saitoh M Yamakido Y Taooka D Sheppard, J Biol Chem 1999 274 36328 36334 10.1074/jbc.274.51.36328 10593924
174. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. LL Smith HK Cheung LE Ling J Chen D Sheppard R Pytela CM Giachelli, J Biol Chem 1996 271 28485 28491 10.1074/jbc.271.45. 28485 8910476
175. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. W Zheng R Li H Pan D He R Xu TB Guo Y Guo JZ Zhang, Arthritis Rheum 2009 60 1957 1965 10.1002/art.24625 19565503
176. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Y Hamada K Yuki M Okazaki W Fujitani T Matsumoto MK Hashida K Harutsugu K Nokihara M Daito N Matsuura J Takahashi, Dent Mater J 2004 23 650 655 15688734
177. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. CM Giachelli D Lombardi RJ Johnson CE Murry M Almeida, Am J Pathol 1998 152 353 358 9466560
178. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. CF Lai V Seshadri K Huang JS Shao J Cai R Vattikuti A Schumacher AP Loewy DT Denhardt SR Rittling DA Towler, Circ Res 2006 98 1479 1489 10.1161/01.RES.0000227550.00426.60 16709900
179. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. N Yamamoto F Sakai S Kon J Morimoto C Kimura H Yamazaki I Okazaki N Seki T Fujii T Uede, J Clin Invest 2003 112 181 188 12865407
180. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. CM Giachelli R Pichler D Lombardi DT Denhardt CE Alpers SM Schwartz RJ Johnson, Kidney Int 1994 45 515 524 10.1038/ki.1994.67 8164440
181. Osteopontin mRNA expression in a chemically-induced model of atherogenesis. AR Parrish KS Ramos, Ann N Y Acad Sci 1995 760 354 356 10.1111/j.1749-6632.1995.tb44655.x 7785915
182. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Y Matsui SR Rittling H Okamoto M Inobe N Jia T Shimizu M Akino T Sugawara J Morimoto C Kimura, et al. Arterioscler Thromb Vasc Biol 2003 23 1029 1034 10.1161/01.ATV.0000074878.29805.D0 12730087
183. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. MY Speer MD McKee RE Guldberg L Liaw HY Yang E Tung G Karsenty CM Giachelli, J Exp Med 2002 196 1047 1055 10.1084/jem.20020911 12391016
184. Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. E Atalar E Ozturk N Ozer IC Haznedaroglu A Kepez S Coskun S Aksoyek K Ovunc S Kes S Kirazli F Ozmen, Am J Cardiol 2006 98 817 820 10.1016/j.amjcard. 2006.04.019 16950193
185. Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. PJ Yu A Skolnick G Ferrari K Heretis P Mignatti G Pintucci B Rosenzweig J Diaz-Cartelle I Kronzon G Perk, et al. J Thorac Cardiovasc Surg 2009 138 196 199 10.1016/j.jtcvs.2008.10.045 19577079
186. Expression of osteopontin in calcified coronary atherosclerotic plaques. HM Kwon BK Hong TS Kang K Kwon HK Kim Y Jang D Choi HY Park SM Kang SY Cho HS Kim, J Korean Med Sci 2000 15 485 493 11068982
187. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Y Momiyama R Ohmori ZA Fayad T Kihara N Tanaka R Kato H Taniguchi M Nagata H Nakamura F Ohsuzu, Atherosclerosis 2010 210 668 670 10.1016/j.atherosclerosis.2009.12.024 20074733
188. A disheartening story: aprotinin in cardiac surgery. M Lien EB Milbrandt, Crit Care 2006 10 317 10.1186/cc5072 17096866